Updated Data for Metastatic HER2+ Breast Cancer

Video

Ruth O’Regan, MD; Joyce A. O’Shaughnessy, MD; Hope S. Rugo, MD, FASCO; and Debu Tripathy, MD, provide insight regarding recent updates from key clinical trials on the management of metastatic HER2+ breast cancer.

Data from the following clinical trials are discussed:

  • Latest findings from the phase 2 SUMMIT basket trial on neratinib plus trastuzumab plus fulvestrant for HR-positive MBC with activating HER2 mutations (Jhaveri K, et al. 2020 SABCS. Poster PD1-05).

  • Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial (Saura C, et al. 2020 SABCS. Poster PD13-09).

  • Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens (Moy B, et al. 2020 SABCS. Poster PS9-02).

  • Final analysis of PERTAIN: A randomized, 2-arm, open-label, multicenter phase 2 trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor–positive metastatic or locally advanced breast cancer (Arpino G, et al. 2020 SABCS. Poster PD3-02).

  • A randomized, open-label, phase 3 trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study (Yamamoto Y, et al. 2020 SABCS. Poster PD3-11).

  • Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2-positive metastatic breast cancer (Modi S, et al. 2020 SABCS. Poster PD3-06).

  • Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study (Hamilton E, et al. 2020 SABCS. Poster PD3-07).

  • Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status (Hamilton E, et al. 2020 SABCS. Poster PD3-08).

  • Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases (Wardley A, et al. 2020 SABCS. Poster PD13-04).

Related Videos
Reshma Jagsi, MD, DPhil, Emory University
Jane L. Meisel, MD, Emory University
Pooja Advani, MBBS, MD, Mayo Clinic
Nicholas P. McAndrew, MD, MSCE, University of California, Los Angeles Health
Pooja Advani, MBBS, MD